ArticleFrontiers in genetics2026
Long non-coding RNA TGFB2-OT1 as a diagnostic biomarker and ceRNA regulator in rheumatoid arthritis.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Metabolic control of RNA methylation in rheumatoid arthritis: from synovial stress to pathogenic cellular adaptation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction. Growing evidence highlights the critical role of lncRNAs in RA initiation and progression. However, the pathogenic contributions of many lncRNAs remain unclear. Methods: Whole-transcriptome sequencing of PBMCs from 5 RA patients and 5 healthy controls identified differentially expressed lncRNAs. Candidate lncRNAs, selected by fold-change and expression level, were validated via qRT-PCR in an expanded cohort (56 RA, 18 SLE, 20 pSS, and 39 HCs). Diagnostic performance was assessed by ROC analysis, and bioinformatic predictions explored potential miRNA-mRNA-protein interactions and functional mechanisms of lncRNAs. Results: A study identified 2,162 differentially expressed lncRNAs, with 1,212 upregulated and 950 downregulated. Six lncRNAs with notable expression changes were chosen for qRT-PCR validation. TGFB2-OT1(NR_125715.1) and ENST00000413791 were significantly altered in RA PBMCs, with NR_125715.1 showing high diagnostic accuracy (AUC = 0.8610) and RA-specific expression. NR_125715.1 expression correlated positively with rheumatoid factor (r = 0.297, p = 0.036) and anti-cyclic citrullinated peptide antibodies (r = 0.3809, p = 0.0041). Bioinformatics suggested NR_125715.1 might act as a ceRNA regulating E2F2 via miR-6756-3p and interact with the FUS protein, affecting RNA metabolism and inflammatory signaling. No m6A methylation or CpG islands were found. Conclusion: NR_125715.1 shows RA-associated dysregulation in PBMCs and demonstrates diagnostic discrimination in our cohort. Bioinformatic analyses suggest that NR_125715.1 may participate in RA-related regulatory programs, potentially involving a ceRNA axis (miR-6756-3p/E2F2) and a predicted interaction with the RNA-binding protein FUS. These mechanistic inferences are hypothesis-generating and require functional validation in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.